Stimulants in 2026: Meth, Cocaine, and the Prescription Shadow
The fourth wave of the crisis is stimulant-driven. And there's still no FDA-approved medication for stimulant use disorder.
Body — 8 lenses: [Science: monoamine release/reuptake (DA, NE, serotonin) — cocaine blocks; meth releases. Biology: hyperthermia, cardiac strain, neurotoxicity (dopamine terminals with chronic high-dose meth), dental effects (“meth mouth” from dry-mouth + acidic diet, not the drug directly). Psychology: the “euphoria gap” after the acute phase, stimulant psychosis in heavy meth use, ADHD/stimulant diagnosis intersection. Policy: Schedule II (meth, cocaine, Rx stimulants); DEA production quotas; Adderall shortage backstory. Trends: stimulant-involved deaths hit 57,500 in 2022, ~70% co-involving fentanyl — the fourth wave. Social: the crack-era racialized policy legacy and current disparities. Treatment: NO FDA-approved medication for stimulant UD; contingency management has the strongest evidence (RCTs 2–4× retention); CBT, community reinforcement, matrix model. Harm reduction: sleep, hydration, avoiding mixing with depressants, safer-use supplies, drug checking.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.